Controlled Trial of Angiotensin Receptor Blocker (ARB) & Chemokine Receptor Type 2 (CCR2) Antagonist for the Treatment of COVID-19 (CLARITY 2)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT05122182 |
|
Recruitment Status :
Recruiting
First Posted : November 16, 2021
Last Update Posted : March 29, 2022
|
Sponsor:
University of Sydney
Collaborator:
The George Institute for Global Health, India
Information provided by (Responsible Party):
University of Sydney
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Recruiting |
|---|---|
| Estimated Primary Completion Date : | July 14, 2022 |
| Estimated Study Completion Date : | December 29, 2022 |